BridgeMD
Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
EU CTIS ID: 2023-505349-26-00
What this study is testing
To evaluate the impact of a low dose of epinephrine (0.5 mg bolus) versus the standard dose (1 mg bolus) of epinephrine on 28-day survival with a favorable neurological outcome in patients with out-of-hospital cardiac arrest (OHCA) managed by a Mobile Medical Team (MMT).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female, aged ≥18 years.
- Out-of-hospital cardiac arrest for which resuscitation is decided by the SMUR team.
- Medical Out-of-hospital cardiac arrest.
- Affiliated with or beneficiary of a social security plan
You likely can't join if
- Non-medical OHCA (traumatic, drownings, electrocution, asphyxia, overdose, unknown cause).
- out-of-hospital cardiac arrest without advanced life support (Do Not Attempt Resuscitation order, body finding, the decision not to attempt ALS is at the physician’s discretion).
- Individuals referred to in Articles 10, 31, 32, 33 and 34 of Regulation (EU) No 536/2014, including. Pregnant women, birthing or breastfeeding mothers Adults under legal protection measure (such as guardianship, conservatorship) Individuals deprived of liberty due to judicial or administrative decision
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.